 
<!-- PJG STAG 4700 -->

<!-- PJG ITAG l=11 g=1 f=1 -->
(b) 
<!-- PJG /ITAG -->

<!-- PJG ITAG l=11 g=1 f=3 -->
Submission of and effective date of approval of an abbreviated new drug application submitted under section 505(j)
of the act or a 505(b)(2) application
<!-- PJG /ITAG -->

<!-- PJG ITAG l=11 g=1 f=1 -->
. (1) [Reserved] 
<!-- PJG 0012 frnewline -->

<!-- PJG 0012 frnewline -->
(2) If a drug product that contains a new chemical entity was approved after September 24, 1984, in an application submitted
under section 505(b) of the act, no person may submit a 505(b)(2) application or abbreviated new drug application
under section 505(j) of the act for a drug product that contains the same active moiety as in the new chemical entity
for a period of 5 years from the date of approval of the first approved new drug application, except that the 505(b)(2)
application or abbreviated application may be submitted after 4 years if it contains a certification of patent invalidity
or noninfringement described in &sect;314.50(i)(1)(i)(A)(
<!-- PJG /ITAG -->

<!-- PJG ITAG l=11 g=1 f=3 -->
4
<!-- PJG /ITAG -->

<!-- PJG ITAG l=11 g=1 f=1 -->
) or &sect;314.94(a)(12)(i)(A)(
<!-- PJG /ITAG -->

<!-- PJG ITAG l=11 g=1 f=3 -->
4
<!-- PJG /ITAG -->

<!-- PJG ITAG l=11 g=1 f=1 -->
). 
<!-- PJG 0012 frnewline -->

<!-- PJG 0012 frnewline -->
(3) The approval of a 505(b)(2) application or abbreviated application described in paragraph (b)(2) of this section
will become effective as provided in &sect;314.107(b)(1) or (b)(2), unless the owner of a patent that claims the drug,
the patent owner's representative, or exclusive licensee brings suit for patent infringement against the applicant
during the 1-year period beginning 48 months after the date of approval of the new drug application for the new chemical
entity and within 45 days after receipt of the notice described at &sect;314.52 or &sect;314.95, in which case, approval
of the 505(b)(2) application or abbreviated application will be made effective as provided in &sect;314.107(b)(3).

<!-- PJG 0012 frnewline -->

<!-- PJG 0012 frnewline -->
(4) If an application: 
<!-- PJG 0012 frnewline -->

<!-- PJG 0012 frnewline -->
(i) Was submitted under section 505(b) of the act; 
<!-- PJG 0012 frnewline -->

<!-- PJG 0012 frnewline -->
(ii) Was approved after September 24, 1984; 
<!-- PJG 0012 frnewline -->

<!-- PJG 0012 frnewline -->
(iii) Was for a drug product that contains an active moiety that has been previously approved in another application
under section 505(b) of the act; and 
<!-- PJG 0012 frnewline -->

<!-- PJG 0012 frnewline -->
(iv) Contained reports of new clinical investigations (other than bioavailability studies) conducted or sponsored
by the applicant that were essential to approval of the application, the agency will not make effective for a period
of 3 years after the date of approval of the application the approval of a 505(b)(2) application or an abbreviated new
drug application for the conditions of approval of the original application, or an abbreviated new drug application
submitted pursuant to an approved petition under section 505(j)(2)(C) of the act that relies on the information supporting
the conditions of approval of an original new drug application. 
<!-- PJG 0012 frnewline -->

<!-- PJG 0012 frnewline -->
(5) If a supplemental application: 
<!-- PJG 0012 frnewline -->

<!-- PJG 0012 frnewline -->
(i) Was approved after September 24, 1984; and 
<!-- PJG 0012 frnewline -->

<!-- PJG 0012 frnewline -->
(ii) Contained reports of new clinical investigations (other than bioavailability studies) that were conducted
or sponsored by the applicant that were essential to approval of the supplemental application, the agency will not
make effective for a period of 3 years after the date of approval of the supplemental application the approval of a 505(b)(2)
application or an abbreviated new drug application for a change, or an abbreviated new drug application submitted
pursuant to an approved petition under section 505(j)(2)(C) of the act that relies on the information supporting
a change approved in the supplemental new drug application.
<!-- PJG /ITAG -->

<!-- PJG QTAG 04 -->
<!-- PJG /QTAG -->

<!-- PJG 0012 frnewline -->

<!-- PJG 0012 frnewline -->

<!-- PJG ITAG l=21 g=1 f=1 -->
Dated: September 23, 1994. 
<!-- PJG 0012 frnewline -->

<!-- PJG 0012 frnewline -->

<!-- PJG /ITAG -->

<SIGNER>
<!-- PJG ITAG l=06 g=1 f=1 -->
William K. Hubbard, 
<!-- PJG 0012 frnewline -->

<!-- PJG /ITAG -->
</SIGNER>
<SIGNJOB>
<!-- PJG ITAG l=04 g=1 f=1 -->
Interim Deputy Commissioner for Policy. 
<!-- PJG 0012 frnewline -->

<!-- PJG 0012 frnewline -->

<!-- PJG /ITAG -->
</SIGNJOB>
<FRFILING>
<!-- PJG ITAG l=40 g=1 f=1 -->
[FR Doc. 94&hyph;24052 Filed 9&hyph;30&hyph;94; 8:45 am]
<!-- PJG 0012 frnewline -->

<!-- PJG /ITAG -->
</FRFILING>
<BILLING>
<!-- PJG ITAG l=68 g=1 f=1 -->
BILLING CODE 4160&hyph;01&hyph;P
<!-- PJG /ITAG -->
</BILLING>

<!-- PJG 0012 frnewline -->

<!-- PJG /STAG -->
